IP Library Granted Patent US 11,608,511
Granted Patent B2
US 11,608,511 · App. 15/566,320 · Granted Mar 21, 2023

Methods for modifying genomic DNA

Inventors: Linhong Li (North Potomac, MD); Madhusudan Peshwa (Boyds, MD)
Assignee: MaxCyte, Inc.
C12N15/907A61K35/17A61K35/33A61K48/00A61P35/00C12N5/0636C12N5/0646C12N5/0652C12N9/22C12N9/96C12N15/11C12N15/902C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,608,511
App. No.
15/566,320
Granted
Mar 21, 2023
Kind
B2
Abstract

Compositions and methods concern the sequence modification of an endogenous genomic DNA region. Certain aspects relate to a method for site-specific sequence modification of a target genomic DNA region in cells comprising: contacting the cells with an activating composition; transfecting the cells with a transfection composition comprising (a) donor DNA and (b) a DNA digesting agent; wherein the donor DNA comprises: (i) a homologous region comprising nucleic acid sequence homologous to the target genomic DNA region; and (ii) a sequence modification region; and wherein the genomic DNA sequence is modified specifically at the target genomic DNA region.

Claims (11)

1. An in vitro method for site-specific transgene insertion into a target genomic DNA region in isolated mammalian T cells, comprising:

(i) contacting the T cells with an activating composition comprising anti-CD3 and anti-CD28 antibodies to produce activated T cells; and

(ii) transfecting the activated T cells by electroporation two days post activation with a non-viral transfection composition comprising (a) a donor plasmid DNA, (b) a mRNA encoding a Cas9 DNA digesting agent and (c) a guide RNA;

wherein the donor plasmid DNA comprises: a homologous region comprising nucleic acid sequence homologous to the target genomic DNA region; and a transgene of 500-5000 nucleic acids in length; and

wherein the genomic DNA sequence is modified specifically at the target genomic DNA region; wherein the method provides stable transgene expression six days after transfection without selection medium.

2. The method of claim 1 , wherein the donor plasmid DNA is a single-stranded.

3. The method of claim 1 , wherein the isolated mammalian cells are human cells.

4. The method of claim 1 , wherein the isolated mammalian cells are primary cells.

5. The method of claim 1 , wherein the transgene comprises a chimeric antigen receptor (CAR).

6. The method of claim 1 , wherein the transgene is 1000-5000 nucleic acids in length.

7. The method of claim 1 , wherein the concentration of the donor plasmid DNA in the transfection composition is from about 50 μg/m1 to about 500 μg/ml.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2018
From: LI, LINHONG; PESHWA, MADHUSUDAN
To: MAXCYTE, INC.
Reel/Frame 045137/0732 →
Continuity (2)
Provisional Application 62146618 · Apr 13, 2015
Related Publication 20180112235A1 · Apr 26, 2018